Phase II clinical trial exploring the activity of crizotinib in patients with advanced solid tumors induced by causal alterations of specific receptors (ALK and MET/HGF receptor tyrosine kinases) expressed by cancer sells.

E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER0 个研究点目标入组 582 人2013年1月15日

适应症ocally advanced and/or metastatic malignant tumor (anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, papillary renal cell carcinoma type 1, alveolar soft part sarcoma, clear cell sarcoma or alveolar rhabdomyosarcoma) deemed incurable by conventional surgery, radiotherapy, systemic therapy or any other means MedDRA version: 15.1Level: LLTClassification code 10065867Term: Alveolar rhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10002227Term: Anaplastic large cell lymphoma T- and null-cell typesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10001882Term: Alveolar soft part sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: ocally advanced and/or metastatic malignant tumor (anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, papillary renal cell carcinoma type 1, alveolar soft part sarcoma, clear cell sarcoma or alveolar rhabdomyosarcoma) deemed incurable by conventional surgery, radiotherapy, systemic therapy or any other means
发起方: E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
入组人数: 582
状态: 进行中（未招募）
最后更新: 12年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2013年1月15日

结束日期

待定

最后更新

12年前

研究类型

Interventional clinical trial of medicinal product

性别

All

研究者

发起方

E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER

入排标准

入选标准

•Step 1 registration: \*Local diagnosis of locally advanced and/or metastatic malignant tumor (defined befor) deemed incurable by conventional surgery, radiotherapy, systemic therapy or any other means.\* Mandatory shipment of tumor\-containing tissue blocks. Step 2 registration: \*Measurable disease according to RECIST 1\.1 with target lesion of at least 20mm (or 10mm on spiral CT scans). \*Minimum age 15 years, no upper age limit. \*Eastern Cooperative OncologyGroup (ECOG) performance status 0\-2\. \*Adequate hematological function:ANC\=1x109/L, platelets\=30x109/L and hemoglobin\=8g/dl. \*Adequate renal function:serum creatinine \=2xULN.\*Adequeta liver function:Bilirubin \=1\.5xULN. AST and ALT\=2\.5xULN in the qbsence of liver metastases and \=5xULN if liver function abnormalities are due to the underlying malignancy. \*Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow\-up schedule;those conditions should be discussed with the patient before registration in te trial. \*Negative pregnancy test. \*All patients (male and female) of childbearing/reproduxtive potential must use adequate birth control measures during the study treatment period and for at least three months after the last study tratment. \*Written consent before registration. \*Additional inclusion criteria linked to specific tumor type are described in the protocol in section 3\.2
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 1
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 1
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range 1

排除标准

•Step 2 registration: \*Carcinomatous meningitis or leptomeningeal disease. \*Treatment zith any other investigational drug within the past 4 weeks or within less than 4 half\-life times of the investigational drug before tratment with crizotinib (whatever is the longest period). \*Prior therapy directly targeting ALK and/or MET, previous tratment with crizotinib.\*Previous and active malignancy for the last three years with the exception of non\-melanoma skin cancer, localized cervical cancer, localized and presumably cured prostate cancer or adequately treatedbasal or squamous cell skin carcinoma. \*Acute or chronic severe gastrointestinal conditions such as diarrhea or ulcer. \*Current congestive heart failure. \*Ongoing cardiac dysrhythmias of NCI CTCAE Grade \>2\. \*Uncontrolled atrial fibrillation of any grade. \*Pregnant women.